VIP Nasal Spray

VIP is an acronym for Vasoactive Intestinal Polypeptide. This naturally occuring neuropeptide  has changed the life of CIRS sufferers as the last treatment step in the Shoemaker Protocol.  Trials with VIP have positively changed the quality of life of 100% of participants.

VIP is administered as a nasal spray.

VIP is a potent anti-inflammatory and decreases most elevated cytokines. VIP raises low MSH (Melanocyte Stimulating Hormone). VIP increases VEGF (Vascular Endothelial Growth Factor), another peptide that is lowered in CIRS-WDB patients.
VIP has antimicrobial, antifungal and antibacterial properties.

This medication must only be started if the patient has passed an online or in office VCS, has strictly no evidence (after nasal swab test) of MARCONS (biofilm forming coagulase negative staph), and has an ERMI of <2 or a HERTSMI-2 of <10.

Your technique is very important when administering nasal spray.

The diagram above shows the correct way to use nasal spray.
A blood test to confirm a baseline Lipase level is also recommended prior to starting this medication. Lipase is a protein produced by the pancreas to help the body absorb fats. When your pancreas is injured or inflamed it will release more lipase. This can be detected by blood test.
If you report any new nausea, stomach aches or troubling symptoms they may be related to the use of the VIP nasal spray.
An elevated Lipase level could be a contraindication to using this medication or a lower dose may be indicated once a period of abstinence has been observed and your level has dropped to normal. It is advised you work closely with your Physician when using this potent medication.
On the odd occasion a patient simply does not get improvement on VIP or develops a somatic disorder (namely depression). It has been found by experienced Shoemaker Physicians that low grade infections are to blame for this unexpected development. Usually the VIP is stopped until an infection can be discovered, diagnosed and treated. Then the patient will recommence on their starter dose and treatment with VIP will usually progress more smoothly.
Duration of treatment with VIP nasal spray varies considerably,  with timeframes ranging from 30 days to indefinitely. Dosage range can also vary from 1 spray to 16 sprays per day for adults. Paediatric patients will also likely require this final step in the Shoemaker Protocol but use a reduced dosage for a shorter time.
A starter dose for very unwell and sensitive adults or paediatric patients can be as low as 50mcg per spray. Some adults have not recovered to pre-CIRS health until utilising 2000mcg per spray. So dosages vary enormously and must be tailor made to your individual circumstances.